Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Capricor Therapeutics, Inc.

Market Cap 1.49B 1.29B 1.19B 1.11B 2.09B 141B 2.11B 14.02B 5.47B 69.06B 5.61B 5.49B 240B P/E Ratio 2026 *
-32.2x
P/E Ratio 2027 * -33.2x
Enterprise Value 1.49B 1.29B 1.19B 1.11B 2.09B 141B 2.11B 14.02B 5.47B 69.06B 5.61B 5.49B 240B EV / Sales 2026 *
14.3x
EV / Sales 2027 * 14.3x
Free-Float
90.53%
Yield 2026 *
-
Yield 2027 * -
1 day+3.57%
1 week+0.04%
Current month-10.81%
1 month-10.37%
3 months-12.39%
6 months+2.69%
Current year-7.42%
1 week 24.65
Extreme 24.65
26.97
1 month 24.65
Extreme 24.65
30.52
Current year 21.06
Extreme 21.0601
36.82
1 year 4.3
Extreme 4.3
40.37
3 years 2.68
Extreme 2.68
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
54
Manager TitleAgeSince
Chief Executive Officer 62 2013-11-19
Director of Finance/CFO 40 2017-12-31
Chief Tech/Sci/R&D Officer - 2025-05-12
Director TitleAgeSince
Chairman 70 2013-10-31
Director/Board Member 68 2013-11-19
Director/Board Member 79 2013-11-19
Date Insider Type Main position Quantity % Market Cap.
05-25Free

CHIEF COMMERCIAL OFFICER

80,000 0.1383%
05-17Fiscal year

Chief Financial Officer

6,000 0.0104%
05-12Fiscal year

Chairman

7,874 0.0136%
Change 5-day change 1-year change 3-year change Capi.($)
+3.57%+0.04%+126.83%+460.17% 1.49B
-2.86%-0.63%+51.45%+109.01% 56.42B
-0.34%+2.91%+45.55%+46.87% 44.54B
+0.29%+3.09%-14.80%-18.16% 22.9B
-0.40%+3.44%-1.29%+405.24% 21.21B
-0.51%-5.56%+10.43%-29.97% 16.4B
-1.54%+0.66%+7.63%-40.19% 15.4B
-0.24%+0.57%+27.43%+182.22% 13.35B
+0.96%+6.56%+20.81% - 12.36B
+0.32%+1.60%+96.37%+207.56% 11.15B
Average -0.08%+1.15%+37.04%+146.97% 21.52B
Weighted average by Cap. -0.90%+2.50%+31.33%+102.25%

Financials

2026 *2027 *
Net sales 104M 90M 82.88M 77.77M 146M 9.88B 148M 978M 382M 4.82B 391M 383M 16.72B 104M 90.18M 83.04M 77.93M 146M 9.9B 148M 980M 383M 4.83B 392M 384M 16.75B
Net income -42.65M -36.8M -33.89M -31.8M -59.67M -4.04B -60.34M -400M -156M -1.97B -160M -157M -6.84B -48.17M -41.57M -38.28M -35.92M -67.4M -4.56B -68.15M -452M -176M -2.23B -181M -177M -7.72B
Net Debt - -
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
26-06-15 26.72 $ +3.57% 985,485
26-06-12 25.80 $ +3.04% 773,704
26-06-11 25.04 $ -1.14% 1,220,574
26-06-10 25.33 $ -2.61% 1,484,424
26-06-09 26.01 $ -0.57% 976,388
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
25.80USD
Average target price
54.11USD
Spread / Average Target
+109.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPR Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!